Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

Sage Therapeutics has brought a lawsuit against ... to with Biogen,” a Sage spokesperson said in a statement to Fierce Pharma. The two firms joined hands in late 2020 when Biogen signed on ...

Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Sage Therapeutics has a unique approach to targeting ... there’s a trend of recent CNS drugs being acquired by other big pharma companies in the sector. It could also be simply that BIIB saw ...

Anti-abortion groups aren’t lobbying against RFK Jr., U.S. reported first case of H5N9 bird flu strain, Sage Therapeutics ...